A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients.
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
- Focus Biomarker; Therapeutic Use
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 21 Mar 2012 Actual initiation date (Oct 2009) added, additional lead trial investigator (Francine Foss) identified and official title amended as reported by ClinicalTrials.gov.
- 21 Mar 2012 Planned end date (Jul 2013) added as reported by ClinicalTrials.gov.